Advertisement

Rheumatology International

, Volume 8, Issue 5, pp 225–230 | Cite as

Presence of interferon and anti-interferon in patients with systemic lupus erythematosus

  • P. von Wussow
  • D. Jakschies
  • K. Hartung
  • H. Deicher
Originals

Summary

Sera from 61 patients with systemic lupus erythematosus (SLE) were serially screened over a period of at least 2 years for IFN and anti-IFN antibodies. IFN concentrations were measured both with a cytopathic effect assay and a more sensitive radioimmunoassay. Of the patients 15% (9/61) had IFN in their serum at one or more occasions as measured in the bioassay (≥6 IU/ml); employing a RIA (≥1 IU/ml) 28% (17/61) of the patients studied were positive for IFN-α. Fifteen patients had a measurable interferonemia over 2–16 months; only two patients had detectable IFN in their serum at only one occasion. In five patients, hourly and daily variations of the IFN titer as measured by RIA were found to amount to less than 80%. The IFN activity found in these sera was characterized as IFN-α by means of acid stability, cross-reactivity on heterologous cells, trypsin sensitivity, and neutralization by homologous and heterologous antisera. IFN antibodies were quantified with a neutralization bioassay, an ELISA, and a radioimmunoassay. Of the 61 patients 5% (3) possessed high titers of anti-IFN antibodies which persisted over 2 years. The IFN-α antibody positive patients had an inactive form of the disease over years without visceral involvement but decreased serum complement levels (C4, C3, CH50) and repeated episodes of Quincke-like edema.

Key words

SLE IFN-α Anti-IFN-α antibodies 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Branca AA, Baglioni C (1981) Evidence that types I and II interferons have different receptors. Nature 294:768–770Google Scholar
  2. 2.
    Stewart II WE (1981) VI. Interferon production. In: The IFN system. Springer, Berlin Heidelberg New YorkGoogle Scholar
  3. 3.
    Kirchner H, Zawatzky R, Engler H, Schirrmacher V, Becker H, von Wussow P (1979) Production of IFN in the mixed lymphocyte culture. II. IFN production is a T cell dependent function, independent of proliferation. Eur J Immunol 9:824–826Google Scholar
  4. 4.
    Stringfellow DA (1983) Nonpolynucleotide inducers of interferon. In: Came PE, Carter WA (eds) Handbook of experimental pharmacology, vol 71. Springer, Berlin Heidelberg New YorkGoogle Scholar
  5. 5.
    Skurkovich SV, Eremkina EI (1975) The probable role of IFN in allergy. Ann Allergy 35:356–360Google Scholar
  6. 6.
    Hooks JJ, Montsopoulos HM, Notkins AL (1979) Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301:5–8Google Scholar
  7. 7.
    Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J (1982) Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leucocyte interferon. Science 216:429–431Google Scholar
  8. 8.
    Ytterberg SR, Schnitzer TJ (1982) Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 25:401–406Google Scholar
  9. 9.
    Wussow P von, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H (1987) Clinical significance of anti-IFN-α antibody titers during IFN therapy. Lancet II:635–636Google Scholar
  10. 10.
    Ho M, Enders JF (1959) An inhibitor of viral activity appearing in infected cell cultures. Proc Natl Acad Sci USA 45:385–389Google Scholar
  11. 11.
    Parry RP, Parry JV (1981) Interferon assay as a diagnostic test. Lancet I:506–507Google Scholar
  12. 12.
    Hooks JJ, Jordan WG, Cuppos T, Montsopoulos HM, Fauci AS, Notkins AL (1982) Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum 25:396–400Google Scholar
  13. 13.
    Capou DJ, Shepard HM, Goeddel DV (1985) Two distinct families of human and bovine interferon-α genes are coordinately expressed and encode functional polypeptides. Mol Cell Biol 5:768–779Google Scholar
  14. 14.
    Spiegel J, Spicehandler JR, Jacobs SL, Oden EM (1986) Low incidence of serum neutralizing factors in patients receiving recombinant alpha 2b interferon. Am J Med 80:223–228Google Scholar
  15. 15.
    Itri LM, Campion M, Dennice R, Palleroni A, Gutterman JU, Groopman J, Trowce PW (1987) Incidence and clinical significance of neutralizing antibodies in patients receiving Roferon A by intramuscular injection. Cancer 59:668–674Google Scholar
  16. 16.
    Sergiescu D, Cerutti I, Ethymiou E, Kakan A, Chany C (1979) Adverse effects of interferon treatment on the life span of NZB mice. Biomedicine 31:48–51Google Scholar
  17. 17.
    Heremans H, Billian A, Colombatti, Hilgers J, Somer P de (1978) Interferon treatment of NZB mice; accelerated progression of autoimmune disease. Infect Immun 21:925–930Google Scholar
  18. 18.
    Adam C, Thoua Y, Ronco P, Verroust P, Tovey MG, Morel-Maroger L (1980) The effect of exogenous interferon: acceleration of autoimmune and renal disease in (NZB/W) F1 mice. Clin Exp Immunol 40:373–382Google Scholar
  19. 19.
    Rotem Z, Cox RA, Isaac A (1963) Inhibition of virus multiplication by foreign nucleic acid. Nature 197:564–566Google Scholar
  20. 20.
    Eyser E, Geodert J, Poon MC, Preble O (1983) Acid-labile alpha interferon. A possible preclinical marker for the acquired immunodeficiency syndrome in hemophilia. N Engl J Med 304:583–586Google Scholar
  21. 21.
    Kennedy P, Narayan N, Ghotbi Z, Hopkins J, Gendleman H, Clements JE (1985) Persistent expression of I a antigen and viral genome in Visna-Maedi virus-induced inflammatory cells. Possible role of lentivirus-induced interferon. J Exp Med 162:1970–1982Google Scholar
  22. 22.
    Cohen AS, Reynolds WE, Franklin EC, Kulka JP, Ropes MW, Shulman LE, Wallace SL (1971) Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 21:643–648Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • P. von Wussow
    • 1
  • D. Jakschies
    • 1
  • K. Hartung
    • 1
  • H. Deicher
    • 1
  1. 1.Abteilung Immunologie und Transfusionsmedizin, Zentrum Innere Medizin und DermatologieMedizinische HochschuleHannover 61Federal Republic of Germany

Personalised recommendations